Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Insulin sensitisation to delay pubertal progression in girls: a pilot study in small-for-gestational-age (SGA) girls with an early-normal onset of puberty
ISRCTN ISRCTN06805028
ClinicalTrials.gov identifier
Public title Insulin sensitisation to delay pubertal progression in girls: a pilot study in small-for-gestational-age (SGA) girls with an early-normal onset of puberty
Scientific title
Acronym Metformin-Puberty
Serial number at source N/A
Study hypothesis Modulation of insulin-signalling contributes to variation in the tempo of pubertal progression in girls.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment Spain
Disease/condition/study domain Advanced and progressive puberty in low-birthweight girls, resulting in final height below target
Participants - inclusion criteria 1. Birthweight for gestational age below -1.5 standard deviation (SD)
2. Onset of breast development (Tanner stage 2, B2) between age 8-9 years and <12 months before study start
3. Height SD score (SDS) at enrollment at least 1 SD above mid-parental height
4. Height velocity >6 cm/year
5. Progressive puberty, as assessed by pelvic ultrasonography and by gonadotropin and steroid responses to gonadotropin releasing hormone (GnRH) agonist stimulation
Participants - exclusion criteria A family or personal history of diabetes mellitus; a history of precocious pubarche; evidence for thyroid dysfunction, Cushing syndrome, hyperprolactinemia or glucose intolerance; medication known to affect gonadal function or carbohydrate metabolism.
Anticipated start date 20/10/2002
Anticipated end date 25/06/2006
Status of trial Completed
Patient information material
Target number of participants 22
Interventions Insulin sensitisation: metformin 850 mg/day versus placebo
Primary outcome measure(s) 1. Menarche
2. Final height
Secondary outcome measure(s) 1. Fasting insulin
2. IGF-I
Sources of funding Hospital Sant Joan de Déu (Spain)
Trial website
Publications 2006 results in http://www.ncbi.nlm.nih.gov/pubmed/16492692
2007 results in http://www.ncbi.nlm.nih.gov/pubmed/17608755
Contact name Prof  Lourdes  Ibañez
  Address Hospital Sant Joan de Déu
University of Barcelona
  City/town Esplugues
  Zip/Postcode 08950
  Country Spain
Sponsor Hospital Sant Joan de Deu (Spain)
  Address University of Barcelona
Passeig de Sant Joan de Déu, 2
  City/town Esplugues
  Zip/Postcode 08950
  Country Spain
Date applied 24/08/2005
Last edited 11/09/2009
Date ISRCTN assigned 05/10/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central